Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

Clinical trial NCT07494305 · RECRUITING

Trial details

NCT number: NCT07494305
Sponsor: LB Pharmaceuticals Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Bipolar I Disorder

Start date: 2026-01-23
Primary completion: 2028-02-01
Enrollment: 320

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.